GFPC
ADMA icon

Global Financial Private Client’s ADMA Biologics ADMA Stock Holding History

Global Financial Private Client’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24
Closed -$476 – 244
2025
Q1 		$476 Buy
24
+19
+380% +$329 ﹤0.01% 1294
2024
Q4 		$86 Buy
+5
New +$94 ﹤0.01% 1510

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Global Financial Private Client's ADMA Position: Q2 2025 in Review

Global Financial Private Client sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 24 shares — an estimated $476 sold.

Global Financial Private Client first reported a position in ADMA in Q4 2024 and held it in 2 quarters. The position peaked at $476 in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Global Financial Private Client reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Global Financial Private Client sold 24 ADMA Biologics shares in Q2 2025, an estimated $476.
  • Global Financial Private Client first reported a position in ADMA Biologics in Q4 2024 and held it in 2 quarters.
  • Global Financial Private Client's ADMA Biologics position peaked at $476 in Q1 2025.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.